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Abstract
Background: Cigarette smoking is an established risk factor of lung cancer development while the current
epidemiological evidence is suggestive of an increased lung cancer risk associated with alcohol consumption.
Dietary folate, which is present in a wide range of fresh fruits and vegetables, may be a micronutrient that has a
beneficial impact on lung carcinogenesis. Methylenetetrahydrofolate reductase (MTHFR) plays a crucial role in
regulating folate metabolism, which affects both DNA synthesis/repair and methylation. We examined if smoking
or alcohol consumption modify associations between MTHFR polymorphisms and lung cancer risk.
Methods: We evaluated the role of the MTHFR C677T (rs1801133) and A1298C (rs1801131) polymorphisms in a
case-control study comprised of 462 lung cancer cases and 379 controls in a Japanese population. Logistic
regression was used to assess the adjusted odds ratios (OR) and 95% confidence intervals (95% CI).
Results: The TT genotype of the C677T polymorphism was significantly associated with an increased risk of lung
cancer (OR = 2.27, 95% CI = 1.42 - 3.62, P < 0.01) while the A1298C polymorphism was not associated with lung
cancer risk. The minor alleles of both polymorphisms behaved in a recessive fashion. The highest risks were seen for
677TT-carriers with a history of smoking or excessive drinking (OR = 6.16, 95% CI = 3.48 - 10.9 for smoking; OR = 3.09,
95% CI = 1.64 - 5.81 for drinking) compared with C-carriers without a history of smoking or excessive drinking, but no
interactions were seen. The 1298CC genotype was only associated with increased risk among non-smokers (P < 0.05),
and smoking was only associated with increased risks among 1298A-carriers (P < 0.01), but no significant interaction
was seen. There was a synergistic interaction between the A1298C polymorphism and drinking (P < 0.05). The
highest risk was seen for the CC-carriers with excessive drinking (OR = 7.24, 95% CI = 1.89 - 27.7) compared with the
A-carriers without excessive drinking).
Conclusions: The C677T polymorphism was significantly associated with lung cancer risk. Although the A1298C
polymorphism was not associated with lung cancer risk, a significant interaction with drinking was observed.
Future studies incorporating data on folate intake may undoubtedly lead to a more thorough understanding of the
role of the MTHFR polymorphisms in lung cancer development.
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Lung cancer remains one of the major causes of mortality
worldwide [1]. Although cigarette smoking is the primary
risk factor for lung cancer, approximately one in 10 smo-
kers develops lung cancer in their lifetime indicating an
interindividual variation in susceptibility to tobacco
smoke [2]. Other factors such as dietary factors may also
play an important role in the etiology of lung cancer.
Convincing evidence shows an inverse association
between fruit and vegetable intake and lung cancer risk
[3-5].
Genetic host factors have been implicated in some of
the observed differences in susceptibility. To date, candi-
date susceptibility genes for lung cancer have been exten-
sively studied, with most of the work focusing on
mechanistically plausible polymorphisms in genes coding
for enzymes involved in the activation, detoxification and
repair of damage caused by tobacco smoke. In addition
to metabolic polymorphisms, functional polymorphisms
in folate metabolizing genes can also be good candidate
susceptibility polymorphisms for lung cancer susceptibil-
ity. Folate, which is unsynthesizable by humans, is one of
the major components of fruits and vegetables and may
exert a beneficial impact on lung carcinogenesis [6].
Methylenetetrahydrofolate reductase (MTHFR), a key
enzyme in folate metabolism, irreversibly catalyzes the
conversion of 5,10-methylenetettrahydrofolate (5,10-
methylene THF) to 5-methyltetrahydrofolate (5-methly
THF). Two common functional MTHFR polymorphisms,
C677T (rs1801133, A222V) and A1298C (rs1801131,
E429A), have been the most studied. The TT genotype of
the C677T polymorphism results in 30% enzyme activity
in vitro compared with the CC genotype [7], whereas the
CC genotype of the A1298C polymorphism has 60%
enzyme activity of the AA genotype in vitro [8,9]. Indivi-
duals with the genotypes involved in reduced enzyme
activity had significantly increased homocysteine levels
and decreased folate levels compared with individuals
with their counterpart genotypes [10]. The importance of
the MTHFR enzyme in cancer susceptibility arises from
its involvement in two pathways of folate metabolism.
5,10-methylene THF is required for DNA synthesis and
DNA repair, and 5-methyl THF is the methyl donor for
regeneration of methionine from homocysteine for sub-
sequent methylation reactions [11,12]. Decrease in the
activity of the MTHFR enzyme increases the pool of
5,10-methylene THF at the expense of the pool of 5-
methyl THF (contributes to downstream methylation
reactions by regeneration of methionine from homocys-
teine). Enhanced availability of 5,10-methylene THF in
the DNA synthesis pathway reduces misincorporation of
uracil into DNA, which might otherwise result in strand
breaks during uracil excision repair, thus increasing the
risk of chromosomal aberrations [11]. Therefore, it is
probable that the decreased availability of 5-methyl THF
for DNA methylation is the crucial mechanism behind
the expected increased risk of lung cancer in subjects
with the genotypes related to low MTHFR activity.
Lung cancer is a common disease that results from a
complex interplay of genetic and environmental risk fac-
tors. It has been reported that there are lower circulating
folate concentrations in smokers than in nonsmokers
[13,14] although a considerable portion of the effect of
cigarette smoking on folate concentrations may be indir-
ect (different intake of smokers and nonsmokers). Alco-
hol consumption has been shown to reduce folate
bioavailability [15]. Smokers (established high risk popu-
lation) or drinkers (suspected high risk population) with
a genotype associated with decreased folate levels may be
more susceptible to lung cancer than expected from the
independent effects of the two (smoking/drinking and
genetic) separate factors. As smoking and drinking may
interact with the MTHFR genotypes to induce lung carci-
nogenesis, we conducted a case-control study of lung
cancer in a Japanese population with special attention to
the interaction between the MTHFR polymorphisms and
either cigarette smoking or alcohol drinking.
Methods
Study subjects and data collection
Lung cancer patients were recruited at Kyushu University
Hospital (Research Institute for Diseases of the Chest,
Kyushu University) and its collaborating hospitals. Eligible
cases were newly diagnosed and histologically confirmed
primary lung cancer during the period from 1996 to 2008.
Histological types were categorized into four major types
according to the International Classification of Diseases for
Oncology (ICD-O), second edition: adenocarcinoma (8140,
8211, 8230-8231, 8250-8260, 8323, 8480-8490, 8550-8560,
8570-8572), squamous cell carcinoma (8050-8076), small
cell carcinoma (8040-8045) and large cell carcinoma (8012-
8031, 8310). The participation rate among the cases was
100%. Three hundred and seventy nine potential controls
were selected from inpatients without having a clinical his-
tory of any type of cancer, past or present, ischemic heart
disease and chronic respiratory diseases who stayed in
departments other than departments of respiratory medi-
cine, such as the department of internal medicine, in the
collaborating hospitals during the same period because
hospital controls are more motivated and are more easily
accessible for obtaining DNA samples. Controls were not,
individually or in larger groups, matched to cases. Controls
were approached by their attending physicians to be
recruited as control subjects. None of the controls refused
to participate in this study. A self-administered question-
naire was used to collect data on demographic and lifestyle
factors such as age, years of education, smoking, alcohol
consumption, environmental tobacco exposure from
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Japanese.
The study protocol was approved by our institutional
review board, and all participants provided written
informed consent.
Genetic analyses
Genomic DNA was extracted from blood samples. Geno-
typing was conducted with blinding to case/control status.
The genotyping of the C677T polymorphism was per-
formed with TaqMan assay (genotyping protocols supplied
centrally by IARC because this single nucleotide poly-
morphism (SNP) genotyping is part of an IARC-oriented
international collaborative study on lung cancer) while the
A1298C genotypes were evaluated independently of the
IARC-oriented international collaborative study on lung
cancer using the PCR-restriction fragment length poly-
morphism (RFLP) method described elsewhere [8]. Gener-
ally, the concordance rate between PCR-RFLP genotyping
and real-time PCR assay is high [16]. For quality control,
both assays were repeated on a random 5% of all samples,
and the replicates were 100% concordant.
Statistical analysis
To test for associations between SNPs and lung cancer, we
defined the ancestral allele using the National Center for
Biotechnology Information SNP database as the major
allele. We assessed HWE via a goodness-of-fit c
2 test
(Pearson) to compare the observed and expected genotype
frequencies among controls. Based on the results from
functional studies and the associations between MTHFR
polymorphisms and lung cancer, we designated the geno-
type that is presumed to increase the risk of lung cancer
as the “at-risk” genotype. The trend of association was
assessed by a logistic regression model assigning ordinal
scores to the levels of the independent variable. Uncondi-
tional logistic regression was used to compute the odds
ratios (ORs) and their 95% confidence intervals (CIs), with
adjustments for several covariates found to be associated
with risk (age, sex, smoking status and education). Subjects
were considered current smokers if they had smoked or
stopped smoking less than one year before either the date
of diagnosis (lung cancer patients) or the date of comple-
tion of the questionnaires (controls). Non-smokers were
defined as those who had never smoked in their lifetime.
Former smokers were those who had stopped smoking
one or more years before either the date of diagnosis of
lung cancer (lung cancer patients) or the date of comple-
tion of the questionnaires (controls). Based on “Healthy
Japan 21” (National Health Promotion in the 21st Cen-
t u r y ) ,h e a v yd r i n k e r sw e r ed e f i n e da st h o s ew h od r a n k
more than 60 g per day of alcohol [17]. As “Healthy Japan
21” has emphasized drinking an appropriate volume of
alcohol (20 g of alcohol per day), appropriate drinkers
were defined as those who did not exceed 20 g of alcohol
intake per day. The appropriate volume of alcohol use
may have a protective effect on life expectancy and mor-
bidity [18]. Moderate drinkers were defined as those who
drank alcohol more than 20 g per day but not exceeding
60 g per day. Unlike cigarette smoking, ingested alcohol is
eliminated from the body by various metabolic mechan-
isms, and the alcohol elimination process begins almost
immediately. Significant relationships between excessive
drinking and lung cancer have been reported while appro-
priate drinking has not shown the same effects [19]. In
terms of alcohol consumption, the subjects were classified
into the following two groups based on their intake for at
least one year as follows: those who drink more than 20 g
of alcohol per day (excessive drinkers) and those who
drink less than 20 g of alcohol per day (appropriate drin-
kers). The interaction between MTHFR polymorphisms
and smoking/drinking on the risk of lung cancer was sta-
tistically evaluated based on the likelihood test, comparing
the models with and without (multiplicative scale) terms
for interaction. We used two logistic regression models to
specifically test for dominant versus recessive inheritance
of the effects of the T allele. In the dominant model, we
hypothesized that the MTHFR C677T (A1298C) genotypes
CT (AC) and TT (CC) contributed equally to lung risk,
and we coded CC (AA) = 0, CT (AC) = 1 and TT (CC) =
1. In the recessive model, we hypothesized that only the
TT (CC) genotype contributed to the risk of the disease,
and we coded CC (AA) = 0, CT (AC) = 0 and TT (C) = 1.
The log-likelihood statistics of each model were compared
with the general logistic regression log likelihood that
jointly fitted both dominant and recessive effects. Linkage
disequilibrium between the C677T and A1298C poly-
morphisms was calculated with HaploView software ver-
sion 4.2 [20].
All statistical analyses were performed using the compu-
ter program STATA Version 10.1 (STATA Corporation,
College Station, TX). All P values were two-sided, with
those less than 0.05 considered statistically significant.
Results
The distributions of selected characteristics among study
subjects are summarized in Table 1. Our analysis included
462 lung cancer patients (242 with adenocarcinoma, 131
with squamous cell carcinoma, 69 with small cell carci-
noma, and 20 with large cell carcinoma). As controls were
not selected to match lung cancer patients on age and sex,
there was a significant difference in age (P < 0.01) and sex
ratio (P < 0.01) between lung cancer patients and controls.
Similarly, there were significant differences between cases
and controls in terms of sex ratio, smoking status, pack-
years of smoking and years of education.
As shown in Table 2, the frequencies of the CC
(ancestral based on National Center for Biotechnology
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the MTHFR C677T polymorphism were 33.1%, 43.5%
and 23.4% in cases and 41.7%, 44.9% and 13.5% in con-
trols, respectively. The genotype distribution of the
C677T polymorphism was consistent with HWE among
controls (PHWE = 0.62). The distributions of the AA
(ancestral), AC and CC genotypes of the A1298 poly-
morphism were 60.2%, 33.3% and 6.49% in cases and
63.1%, 32.2% and 4.75% in controls, respectively. This
polymorphism was also in HWE among controls (PHWE
= 0.63). The TT genotype of the C677T polymorphism
was significantly associated with an increased risk of
lung cancer compared with the CC genotype (adjusted
OR = 2.27, 95% CI = 1.42 - 3.63, P < 0.01). With the
CC genotype as reference, the OR for the combined TT
and CT genotypes was 1.49 (95% CI = 1.08 - 2.07, P =
0.02) (dominant model). Comparing the dominant
m o d e lw i t ht h eg e n e r a lm o d e l ,t h ec
2 value was 6.37
(P = 0.01), so the dominant model was rejected. Using
the CC and CT genotypes combined as the reference,
t h eO Rf o rt h eT Tg e n o t y p ew a s2 . 0 0( 9 5 %C I=1 . 3 0-
3.07, P < 0.01), and the c
2 value of the recessive model
Table 1 Selected characteristics of lung cancer cases and controls
Characteristics Cases (n = 462) Controls (n = 379) P
Age (year), median (IQR) 68 (62 - 73) 58 (48 - 65) <0.01
Male, n (%) 287 (62.1) 283 (74.7) <0.01
Smoking status, n (%) <0.01
Current smoker 198 (42.9) 129 (34.0)
Former smoker 111 (24.0) 41 (10.8)
Never smoker 153 (33.1) 209 (55.2)
Pack years, median (IQR) 38 (0 - 58) 0 (0 - 34) <0.01
Moderate/heavy drinkers, n (%) 284 (61.5) 175 (46.2) <0.01
Exposure to environmental tobacco smoke among non-smokers, n (%) 99 (64.7) 135 (64.6) 0.98
Education, median (IQR) 12 (12 - 16) 16 (12 - 16) <0.01
Histology, n (%)
Adenocarcinoma 242 (52.4)
Squamous cell carcinoma 131 (28.4)
Small cell carcinoma 69 (14.9)
Large cell carcinoma 20 (4.3)
IQR, interquartile range
Table 2 Association between the MTHFR polymorphisms and risk of lung cancer
Number (%) of OR (95% CI)
Polymorphism Cases Controls PHWE
† Crude P Adjusted* P
C677T
CC (ancestral**) 153 (33.1) 158 (41.7) 1.0 (reference) - 1.0 (reference) -
CT 201 (43.5) 170 (44.9) 1.22 (0.90 - 1.65) 0.20 1.27 (0.90 - 1.80) 0.18
TT 108 (23.4) 51 (13.5) 0.62 2.19 (1.47 - 3.26) <0.01 2.27 (1.42 - 3.62) <0.01
Dominant model
CT + TT vs.CC
1.44 (1.09 - 1.91) 0.01 1.49 (1.08 - 2.07) 0.02
Recessive model
TT vs. CT + CC
1.96 (1.36 - 2.83) <0.01 2.00 (1.30 - 3.07) <0.01
A1298C
AA (ancestral**) 278 (60.2) 239 (63.1) 1.0 (reference) - 1.0 (reference) -
AC 154 (33.3) 122 (32.2) 1.08 (0.81 - 1.46) 0.59 0.97 (0.69 - 1.35) 0.84
CC 30 (6.49) 18 (4.75) 0.63 1.43 (0.78 - 2.64) 0.25 1.55 (0.76 - 3.17) 0.23
Dominant model
AC + CC vs. AA
1.13 (0.85 - 1.49) 0.39 1.03 (0.75 - 1.42) 0.85
Recessive model
CC vs. AC + AA
1.39 (0.76 - 2.54) 0.28 1.57 (0.77 - 3.18) 0.21
* Adjusted for age, sex, education, smoking status and drinking.
** Defined by National Center for Biotechnology Information SNP database.
† P for Hardy-Weinberg equilibrium test among controls.
Kiyohara et al. BMC Cancer 2011, 11:459
http://www.biomedcentral.com/1471-2407/11/459
Page 4 of 10was 1.81 (P = 0.18) against the general model. These
findings suggest a recessive effect of the T allele on lung
cancer risk. On the other hand, the association of
rs18001131 with lung cancer was not significant in the
general, dominant and recessive models. The c
2 value of
the dominant model was 1.60 (P = 0.21) against the
general model while that of the recessive model was
0.041 (P = 0.84). These findings suggest that the reces-
sive model fits better than the dominant model. Based
on the results of the likelihood ratio test, subjects with
at least one ancestral allele were bundled in one group
for subsequent analysis. A high degree of linkage dise-
quilibrium was observed between the C677T and
A1298C polymorphisms (D’ =0 . 9 3 ,r
2 = 0.26; data not
shown).
Table 3 shows the modifying effect of the C677T geno-
types on the association of smoking or drinking with
lung cancer risk. To achieve adequate statistical power,
current and former smokers were combined (ever-smo-
kers). A history of smoking (adjusted OR = 3.17; 95%
CI = 2.28 - 4.40, P < 0.01) and excessive drinking
(adjusted OR = 1.76; 95% CI = 1.27 - 2.43, P < 0.01) were
associated with an increased risk of lung cancer (data not
shown). Smokers with the TT genotype (“at-risk” geno-
type) (adjusted OR = 6.16, 95% CI = 3.48 - 10.9, P < 0.01)
had a significantly higher risk of lung cancer than non-
smokers with at least one C allele (reference). The “at-
risk” genotype was associated with an increased risk of
lung cancer in both non-smokers (OR = 1.95, 95% CI =
0.99 - 3.84, P = 0.053) and ever-smokers (OR = 1.97, 95%
CI = 1.14 - 3.12, P = 0.015, data not shown). Ever-smok-
ing was associated with an increased risk of lung cancer
in both subjects with at least one C allele (OR = 3.03,
95% CI = 2.12 - 4.34, P < 0.01) and those with the “at-
risk” genotype (OR = 3.17, 95% CI = 1.35 -7.41, P < 0.01,
data not shown). The multiplicative interaction between
the C677T genotypes and smoking was far from
significant (P = 0.93). Similarly, excessive drinkers with
the “at-risk” genotype (adjusted OR = 3.09, 95% CI =
1.64 - 5.81, P < 0.01) had a higher risk of lung cancer
than appropriate drinkers with at least one C allele (refer-
ence). The “at-risk” genotype was associated with an
increased risk of lung cancer in both appropriate drinkers
(OR = 2.46, 95% CI = 1.37 - 4.43, P < 0.01) and excessive
drinkers (OR = 1.58, 95% CI = 0.86 - 2.89, P = 0.14, data
not shown). Excessive drinking was significantly associated
with an increased risk of lung cancer in subjects with at
least one C allele (OR = 1.97, 95% CI = 1.38 -2.82, P <
0 . 0 1 )b u tn o ti nt h o s ew i t ht h e“at-risk” genotype (OR =
1.22, 95% CI = 0.52 - 2.82, P = 0.65, data not shown). No
evidence of interaction between the C667T polymorphism
and drinking was detected (Pinteraction = 0.30).
We assessed interactions between the A1298C poly-
morphism and smoking or drinking. As shown in Table 4,
smokers with the CC genotype (“at-risk” genotype)
(adjusted OR = 3.15, 95% CI = 1.24 - 7.98) had a signifi-
cantly higher risk of lung cancer than non-smokers with at
least one A allele (reference). The “at-risk” genotype was
significantly associated with an increased risk of lung can-
cer in non-smokers (OR = 2.82, 95% CI = 1.02 - 7.83, P =
0.049) but not in ever-smokers (OR = 0.88, 95% CI = 0.35
- 2.02, P = 0.79, data not shown). Ever-smoking was signif-
icantly associated with an increased risk of lung cancer in
subjects with at least one C allele (OR = 3.40, 95% CI =
2.42 -4.78, P < 0.01) but not in those with the “at-risk”
genotype (OR = 0.86, 95% CI = 0.17 - 4.26, P = 0.86, data
not shown). There was no significant interaction between
the A1298C polymorphism and smoking (Pinteraction =
0.11). Excessive drinkers with the “at-risk” genotype
(adjusted OR = 7.24, 95% CI = 1.89 - 27.7, P < 0.01) had a
higher risk of lung cancer than those with at least one A
allele (adjusted OR = 1.64, 95% CI = 1.18 - 2.29, P < 0.01),
relative to appropriate drinkers with at least one A allele
(reference). The “at-risk” genotype was significantly
Table 3 Interaction of the MTHFR C677T polymorphism and cigarette smoking or alcohol drinking
Non-smokers Ever-smokers
Genotype Cases/ OR (95% CI) Cases/ OR (95% CI)
Controls Crude P Adjusted* P Controls Crude P Adjusted* P
CC + CT 126/181 1.0 (reference) - 1.0 (reference) - 228/147 2.23 (1.64 - 3.03) <0.01 3.03 (2.12 - 4.34) <0.01
TT 27/28 1.39 (0.78 - 2.46) 0.28 1.95 (0.99 - 3.84) 0.05** 81/23 5.06 (3.02 - 8.47) <0.01 6.16 (3.48 - 10.9) <0.01
Crude Pinteraction = 0.21 and adjusted Pinteraction = 0.93
Appropriate drinkers Excessive drinkers
Genotype Cases/ OR (95% CI) Cases/ OR (95% CI)
Controls Crude P Adjusted* P Controls Crude P Adjusted* P
CC + CT 128/177 1.0 (reference) - 1.0 (reference) - 226/151 2.07 (1.52 - 2.81) <0.01 1.97 (1.38 - 2.82) <0.01
TT 50/27 2.56 (1.52 - 4.31) <0.01 2.46 (1.37 - 4.43) <0.01 58/24 3.34 (1.97 - 5.66) <0.01 3.09 (1.64 - 5.81) <0.01
Crude Pinteraction = 0.22 and adjusted Pinteraction = 0.30
* Adjusted for age, sex, education and smoking or drinking.
**Exact P = 0.053.
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sive drinkers (OR = 3.96, 95% CI = 1.08 - 14.5, P < 0.01,
data not shown) but not in appropriate drinkers (OR =
0.86, 95% CI = 0.35 - 2.16, P = 0.76). Excessive drinking
was significantly associated with an increased risk of lung
cancer in both subjects with at least one A allele (OR =
1.64, 95% CI = 1.18 - 2.29, P < 0.01) and those with
the “at-risk” genotype (OR = 11.8, 95% CI = 1.81 - 76.5,
P = 0.01, data not shown). The multiplicative (synergistic)
interaction measure was statistically significant (Pinteraction
= 0.049).
Discussion
The present study showed that the TT genotype of the
MTHFR C677T polymorphism was significantly asso-
ciated with an increased risk of lung cancer (OR = 2.27,
95% CI = 1.42 - 3.62, P < 0.01). Although the MTHFR
A1298C polymorphism was not associated with lung
cancer risk, there was a significant synergistic interac-
tion between the A1298C polymorphism and alcohol
consumption (Pinteraciton = 0.049).
Among controls, the prevalences of the C allele of the
C677T polymorphism and the A allele of the A1298C
polymorphism were 64.1% and 79.1%, respectively (data
not shown). According to the HapMap SNP database
[21], the C allele frequency of the C677T polymorphism
is most common among Yorubas (a West African ethnic
group, 89.7%) and least common among Han Chinese
(48.9%); Japanese (63.3%) and Caucasians (76.3%) have
intermediate frequencies. The frequency of the C allele
in our study was similar to the HapMap SNP database.
Meanwhile, the A allele frequencies of the A1298C poly-
morphism among Caucasians, Han Chinese, Japanese
and Yorubas were 64.2%, 80.0%, 82.2% and 89.2%,
respectively, according to the HapMap SNP database
[22]. The frequency of the A allele in our study was
somewhat lower than the HapMap SNP database but
similar to other Japanese populations [23-25] (79.0%,
78.4% and 78.9%).
A ss h o w ni nT a b l e2 ,t h eT Tg e n o t y p eo ft h eMTHFR
C677T polymorphism was significantly associated with
an increased risk of lung cancer (OR = 2.27, 95% CI =
1.42 - 3.62). Results in terms of the association between
the C677T polymorphism and lung cancer yielded mixed,
variously reporting an increased risk [26-31], a decreased
risk [25,32-35] or no association [36-39]. Two meta-ana-
lyses on the association between lung cancer and the
MTHFR polymorphisms have been published in 2008
[40] and 2009 [41], respectively. The first meta-analysis
[40] based on the published data from eight individual
case-control studies [25-29,32,33,37] reported that the
s u m m a r yO Rf o rt h eT Tg e n o t y p ew a s1 . 1 2( 9 5 %C I=
0.97 -1.28) compared with the CC genotype. The second
meta-analysis [41] reported that the summary OR for the
TT genotype was 1.37 (95% CI = 1.02 - 1.84) when
excluding studies conducted in the USA, where some
common food items are regularly fortified with folate
since 1998 [42]. Differences in ethnicity, dietary intake,
exposure to environmental carcinogens and sample size
may be responsible for the discrepancies in the results. It
has been suggested that cancer risk associated with the
MTHFR polymorphisms may be modulated by folate
intake [43,44]. Folate supplements (excessive) have been
shown to increase folic acid levels, reduce homocysteine
levels and then restore normal methionine levels, particu-
larly in these individuals with the TT genotype of the
MTHFR polymorphism [45,46] although the mechanism
remains unclear. Normal methionine levels may not
induce aberrant DNA methylation [43]. When folate is
excess, the C677T polymorphism may not affect lung
cancer risk. Since Japanese drink several cups of green
tea daily and consume substantial vegetables and fruits
[47], folate insufficiency is rare. As the prevalence of
folate supplement users is very low in Japan (0.1%) [48],
Table 4 Interaction of the MTHFR A1298C polymorphism and cigarette smoking or alcohol drinking
Non-smokers Ever-smokers
Genotype Cases/ OR (95% CI) Cases/ OR (95% CI)
Controls Crude P Adjusted* P Controls Crude P Adjusted* P
AA + AC 141/200 1.0 (reference) - 1.0 (reference) - 291/161 2.56 (1.92 - 3.42) <0.01 3.40 (2.42 - 4.78) <0.01
CC 12/9 1.89 (0.78 - 4.61) 0.16 2.82 (1.02 - 7.83) 0.05** 18/9 2.83 (1.23 - 6.50) 0.01 3.15 (1.24 - 7.98) 0.02
Crude Pinteraction = 0.39 and adjusted Pinteraction = 0.11
Appropriate drinkers Excessive drinkers
Genotype Cases/ OR (95% CI) Cases/ OR (95% CI)
Controls Crude P Adjusted* P Controls Crude P Adjusted* P
AA + AC 167/190 1.0 (reference) - 1.0 (reference) - 265/171 1.76 (1.33 - 2.34) <0.01 1.64 (1.18 - 2.29) <0.01
CC 11/14 0.89 (0.40 - 2.02) 0.79 0.86 (0.35 - 2.16) 0.76 19/4 5.40 (1.80 - 16.2) <0.01 7.24 (1.89 - 27.7) <0.01
Crude Pinteraction = 0.08 and adjusted Pinteraction = 0.05†
* Adjusted for age, sex, education and smoking or drinking.
**Exact P = 0.046 †Exact P = 0.049
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Page 6 of 10excessive folate intake is also rare. When folate intake is
sufficient, individuals with the TT genotype of the C677T
polymorphism may have an increased risk of lung cancer,
because decrease in MTHFR activity might lead to
impairment of DNA methylation due to a reduction in
the availability of 5-methyl THF.
The A1298C polymorphism was not associated with
lung cancer risk in the present study. The A1298C poly-
morphism, which has been much less examined, was not
associated with lung cancer risk in this study. Although
the C677T and A1298C polymorphisms are in strong link-
age disequilibrium, the different impacts of the two poly-
morphisms may be expected due to their location within
the protein and subsequent effect on function. The meta-
analysis [40] of seven studies [25-29,33,37] also showed no
association between lung cancer and the A1298C poly-
morphism. Two [33,38] of 10 studies [25-29,31,33,
34,37,38] showed a significant deleterious effect of the CC
genotype of the A1298C polymorphism on lung cancer.
The lower prevalence of the C allele of the A1298C poly-
morphism may make researchers less likely to detect a sig-
nificant association. It is difficult to estimate accurately the
combined effects of the C677T and A1298C polymorph-
isms on lung cancer risk in the current sample size. The
TT genotype of the C677T polymorphism has a greater
impact on enzyme function [7-9]. Moreover, several in
vivo studies demonstrated an association between the TT
genotype of the C677T polymorphism and increased total
homocysteine plasma levels in healthy subjects while lim-
ited and inconsistent data on the role of the A1298C poly-
morphism as determinant of total homocysteine plasma
levels are available [49,50]. The C677T polymorphism may
have confounded the results concerning the A1298C poly-
morphism. Further research on larger study populations is
required before definitive conclusions can be drawn.
It is widely accepted that lung cancer development
requires environmental factors acting on a genetically
predisposed individual. Studying gene-environment inter-
actions in relation to risk of lung cancer may be valuable
because positive findings would clearly implicate the sub-
strates with which the gene interacts as disease-causing
exposures, clarify lung cancer etiology, and point to
environmental modifications for disease prevention. We
evaluated whether an interaction existed between cigar-
ette smoking and the C677T or A1298C polymorphism
(Tables 3 and 4). Interaction refers to the extent to which
the joint effect of two risk factors on lung cancer differs
from the independent effects of each of the factors. Two
risk factors (MTHFR genotype and smoking/drinking)
may act independently or interact thereby increasing or
decreasing the effect of one another. A gene-environment
interaction was suggested, with a combination of the TT
genotype and smoking conferring significantly higher risk
(OR = 6.16, 95% CI = 3.48 - 10.9), compared with at least
one C allele and no history of smoking. Smoking (OR =
3.17) and the TT genotype of the C677T polymorphism
(OR = 2.00) act independently (3.17*2.00 = 6.34 ≈ 6.16).
There was no significant interaction between smoking
and the C677T polymorphism with lung cancer. There
was also no significant effect modification by the A1298C
polymorphism in the association of smoking and lung
cancer (Pinteraction =0 . 1 1 ) .H o w e v e r ,t h er i s ke s t i m a t e s
indicated that smoking and the “at-risk” genotype did not
seem to be associated with increased risk among those
a l r e a d ya ti n c r e a s e dr i s kd u et oo n eo ft h et w of a c t o r s
(smoking/"at-risk” genotype). Eight studies examined the
interaction between smoking and the C677T or A1298C
polymorphism [25,31-35,38,51]. Differences in the direc-
tion and the strength of the interaction were observed.
The difference in circulating folate levels between differ-
ent populations may partly account for the findings
[29,52]. Furthermore, the differences may indicate a dif-
ference in susceptibility among different populations to
smoking-induced lung cancer.
We evaluated the interaction between the C677T or
A1298C polymorphism and alcohol drinking (Tables 3
and 4). Drinking (OR = 1.76) and the TT genotype of the
C677T polymorphism (OR = 2.00) act independently
(1.76*2.00 = 3.52 ≈ 3.09). No interaction of drinking and
the C677T polymorphism with lung cancer was detected
while we found a significant interaction between drinking
and the A1298C polymorphism (Pinteraction = 0.049).
Namely, excessive drinking (OR = 1.76) with the CC gen-
otype (OR = 1.57) had an unexpectedly increased risk of
lung cancer (1.76 *1.57 = 2.76 «7.23). As alcohol inter-
feres with folate absorption and usage [53,54] and serves
as a methyl group antagonist [55], it is biologically plausi-
ble. Four studies examined the interaction between
drinking and the C677T polymorphism [25,29,33,36] or
A1298C polymorphism [25,33]. Statistically significant
interaction between the A1298C polymorphism and alco-
hol consumption was observed in women (Pinteraction =
0.021) but not in men (Pinteraction = 0.569) [33]. Similarly,
a significant interaction between drinking habits and the
A1298C genotype was found (Pinteraction = 0.025) but the
CC genotype of the A1298C polymorphism was asso-
ciated with a lower lung cancer risk (OR = 0.36, 95%
CI = 0.12 - 1.04) [25]. Findings from gene-environment
interaction analyses must be interpreted with caution due
to reduced numbers of observations in the subgroups.
Replication of findings is very important before any cau-
sal inference can be drawn. Testing replication in differ-
ent populations is an important step.
Several limitations of this study warrant mention. Our
study may have included a bias due to the self-reporting of
smoking habits and alcohol consumption (misclassification
bias). However, discrepancies between self-reported smok-
ing habits and biochemical verification are minimal
Kiyohara et al. BMC Cancer 2011, 11:459
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Page 7 of 10among the general population [56,57]. Similarly, the valid-
ity of self-reports on alcohol consumption is generally
high [58,59]. Recall bias is one of well-recognized potential
problems in case-control studies. Lung cancer patients
may remember their exposure with a higher (lower) accu-
racy or completeness than healthy controls do (recall
bias). To use hospital control is one way of minimizing the
impact of recall bias because the controls would generally
have the same incentive as the cases to remember events
in the past [60]. Case-control studies tend to susceptible
to selection bias, particularly in the control group. Con-
trols should represent the source population from which
the cases were drawn. As lung cancer patients are more
likely to be more male sex and be less educated compared
to controls [61], our results on sex ratio and educational
status might not always suggest the existence of selection
bias. When using hospital-based cases, it may not be pos-
sible to define the population which the cases were drawn.
Hospital controls may be more appropriate because the
study population can be defined as potential hospital users
[60]. Generally, the reported participation rates were
slightly higher in hospital-based case-control studies than
in population-based case-control studies [62]. Participation
rates of cases and controls were very high in this study.
High participation rate may reduce the possibility of selec-
tion bias [62]. However, as the possibility of recall and
selection biases could not be completely excluded in case-
control studies, our findings should be interpreted with
caution. Finally, we did not have data on dietary folate
intake. Since smoking is associated with decreased circu-
lating folate levels due to low folate intake [63,64], the
observed interaction between alcohol consumption and
the A1298 C polymorphism may be distorted by residual
confounding by smoking. Additional studies are warranted
to replicate our and others’ findings from case-control
genetic association studies.
Conclusions
The TT genotype of the C677T polymorphism was signifi-
cantly associated with an increased risk of lung cancer.
Although the A1298C polymorphism was not associated
with lung cancer, a significant interaction with drinking
was observed. Smoking interacted with neither the C677T
nor A1298C polymorphism in the development of lung
cancer. Our results should be interpreted cautiously
b e c a u s ew ed i dn o th a v ed a t ao nd i e t a r yf o l a t ei n t a k e .
Future studies involving larger control and case popula-
tions and better exposure histories will undoubtedly lead
to a more thorough understanding of the role of MTHFR
in lung cancer development.
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